EGFR and non-small cell lung carcinoma: Contrastingly, the ATTLAS study demonstrated significantly longer PFS in patients with EGFR/ALK-mutated NSCLC who received ABCP than BCP (8.5 months vs. 5.6 months; HR = 0.62 [95% CI: 0.45–0.86]; p = 0.004).36